source
- PepGen's Phase 2 DM1 Data Show 46% Average Splicing Correction, Shares Jump 163%PepGen reported results from the 10 mg/kg multiple‑ascending‑dose cohort of its ongoing Phase 2 Freedom2‑DM1 trial, testing PGN‑EDODM1, an oligonucleotide designed to correct the molecular defect i…
- Novocure's Optune Mya device denied FDA approval over efficacy concernsNovocure received a "not approvable" letter from the FDA for its Optune Mya system, which was being evaluated for patients with brain metastases from non‑small cell lung cancer after stereotactic r…